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Abstract  
 
DNA Topoisomerase II inhibitors are a type of anticancer drugs. These drugs perform 
their biological activity either by forming a DNA-intercalator-topoisomerase II ternary complex 
or by inhibiting other enzymes and/or transcription factors that act on DNA. The strong 
interactions with DNA play a crucial role for their pharmacological properties. Lunacridine, the 
active principle from Lunasia amara, was known as DNA intercalating Topoisomerase II 
inhibitor. With the aims to explore the affinity and molecular interaction of lunacridine 
compound isolated from Lunasia amara with DNA, molecular docking study has been carried 
out with DNA model using Autodock 4.0 software. Cytotoxicity test on P388 murine leukemia 
cells was done also using 100, 30, 10, 3 and 1 μg/ml series of lunacridine concentration. The 
docking result shows that Lunacridine itself could to dock intercalatively between base pairs of 
DNA and the possibility interaction with adenine, thymine and cytosine by dipole-dipole 
interaction.  The lowest predicted binding  energy of lunacridine is –6,22 kcal/mol, whereas 
original ligand bis thiazole is -16,37 kcal/mol. Lunacridine compound itself has less cytotoxic 
activity on P388 murine leukemia cells with the IC50 value of 39,52 μg/ml or 129,41 μM. The 
binding energy of lunacridine on DNA higher than original ligand show that the interaction of 
lunacridine with DNA is not stable afford the less cytotoxic activity. However, based on the 
IC50 value, lunacridine could be depeloved as anticancer.  
 
Keywords: docking, lunacridine, Lunasia amara, cytotoxic, P388 murine leukimia cells. 
 
 
INTRODUCTION  
 
DNA represents one of the most important 
molecular cellular targets of several anticancer 
drugs. In broad terms, their mechanism of action 
involves interfering with DNA processing, thus 
leading to cell death, usually through invoking 
apoptosis. Agents of this type interact with the 
DNA double helix through a variety of 
mechanisms. Some drugs intercalate between the 
base pairs of DNA, whereas others alkylate DNA 
bases in either the minor or major grooves. Some 
agents cross-link the DNA strands together in 
either an intrastrand or interstrand manner in 
either the minor or major grooves, and yet other 
agents exert their effect by binding to the helix and 
then cleaving the DNA strands (Thurston, 2007). 
DNA Topoisomerase II inhibitors are a type 
of anticancer drugs. These drugs perform their 
biological activity either by forming a DNA-
intercalator-topoisomerase II ternary complex or 
by inhibiting other enzymes and/or transcription 
factors that act on DNA. The strong interactions 
with DNA play a crucial role for their 
pharmacological properties (Filosa, et al., 2009).  
DNA topoisomerase II is an enzyme that 
can eliminate the positive supercoiling formed in 
DNA occurs during DNA replication (Yuwono, 
2008). Mammalian topoisomerase II is very 
important in cellular processes including 
replication, transcription, recombination and 
chromosome segregation (Bromberg and Osheroff, 
2001). Inhibition of this enzyme can inhibit cell 
division and trigger cell death by apoptosis 
mechanism via activation of the P53 gene 
(Martinez, 2005).  
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One of the medicinal plants use traditionally 
in South Sulawesi is Sanrego (Lunasia amara 
Blanco).  This Rutaceae plant   is widely known as 
antibacteria and aphrodisiac. Lunasia amara 
Blanco was known to contain many types of 
alkaloids especially quinoline alkaloids. One of the 
major quinoline alkaloid from Sanrego is 
lunacridine (Goodwin, 1959). Lunacridine had 
been reported as DNA intercalating topoisomerase 
II inhibitor (Prescott, et al., 2007).  
Based on the description above, it had been 
done exploration of the affinity and molecular 
interaction of lunacridine to DNA by molecular 
docking approach and testing its cytotoxic activity 
on P388 murine leukemia cells by MTT method. 
This research is expected to be used as a reference 
in the development effort lunacridine compound to 
be potential and selective anticancer drug. 
 
 
 
 
Figure 1. Stucture of the lunacridine compound. 
 
 
METHODS 
 
Material  
Sanrego lignum (Lunasia amara Blanco) 
collected from the Siawung Village, Barru 
Regency, South Sulawesi Province., TLC plates, 
methanol, n-hexane, ethyl acetate, solvents, 
organic solvents, silica gel PF254, P388 murine 
leukemia cells from Natural Products Organic 
Chemistry Laboratory, Institute of Technology, 
Bandung, RPMI 1640 medium (sigma), with foetal 
bovine serum (FBS) 10%, 2% kanamycin (Gibco), 
Hepes (N-2-hidroxyethil-piperazine-2-
ethanesulfonic acid) (Sigma). HCl (Merck), 
Sodium Bicarbonate (NaHCO3) (Sigma); MTT ([3 
-(4,5-dimethyl thiazole 2-Joel) -2.5-diphenyl 
tetrazolium bromide]) (sigma); Sodium Dodecyl 
Sulphate (SDS) (Merck); Artonin E, and dimethyl 
sulfoxideltetrahydrofuran (DMSO) (Fluka), 
Lunacridine standard from Institute of Natural 
Medicine, Toyama University, Japan, NMR 
structure of the covalent complex between 
d(CGCTAGGCG)-(GCGATCCGC) and original 
ligand bis thiazole obtained from Protein Data 
Bank online database (www.rcsb.org/pdb) with 
access code 108D. 
 
Equipment 
VLC was carried out using Merck Si-gel 60, 
TLC analysis on pre-coated Si-gel plates (Merck 
Kieselgel 60 F254, 0.25 mm). The UV lamp of 
Spectroline, Model ENF-240 C/F was used to see 
the spot in TLC. UV and IR spectra were measured 
with Beckman DU-7000 and Shimadzu FT-IR 
8501 Scientific spectrophotometers respectively. 
For docking simulation using one set of computer 
with specification Intel ® Core™2 Duo CPU 
T5800 @ 2.00 GHz, RAM 2 GB, Microsoft 
Windows Xp SP3 operation system, Autodock 4.0 
software for docking calculations, MGL Tools 
1.5.2, Cygwin, ChemOffice 2004, and Pymol 0.99 
rc 6 for visualitation of the docking result. 
 
Molecular Docking Simulation 
Molecular structure of Lunacridine were 
built using Chem Office 2005 software and 
geometry optimized using PM3 semiempiric 
method. Docking study was carried out based on 
the NMR structure of the covalent complex 
between d(CGCTAGGCG)-(GCGATCCGC) and 
original ligand bis thiazole using AutoDock 4.0 
software. The crystal structure was downloaded 
from the protein Data Bank website 
(www.rscb.org/pdb) with archive code 108D. The 
original ligand structure was removed from the 
structure to provide sterically unimpended cavities 
for ligand docking. Molecular docking calculation 
for Lunacridine at the intercalation sites of DNA 
were undertaken using the Lamarckian Genetic 
Algorithm method with the parameter : a grid box 
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size of 42 x 34 x 40 with spacing of 0.375 Å 
between the grid points, an initial population of 
150 randomly placed individuals, a maximum 
number of 2.5 x 10
5
 energy evaluations, and a 
maximum number of 2.7 x 10
4
 generations are 
taken into account. A mutation rate of 0.02, a 
crossover rate of 0.8 and local search frequency of 
0.06 are used. Data obtained in the form of 
predicted free energy of binding (kcal/mol) and 
predicted inhibition constants (Ki) were recorded 
and analyzed. Validation of the docking are 
determined from the value of RMSD (Root Mean 
Square Deviation) of the original ligand 
conformation from docking results with actual 
original ligand conformation (RMSD value must 
be ≤ 2 Å). Docking results visualized by using 
PyMOL for windows software. 
 
Isolation and Identification of Lunacridine 
Dried lignum (2,1 kg) was extracted by 
reflux method with methanol for 3 x 24 hours. 
Reflux process is repeated as many as two times. 
The filtrate was collected and evaporated to obtain 
viscous methanol extract (16.8 g). Methanol 
extracts then partitioned by using the solvent n-
hexana and ethyl acetate respectively and 
evaporated until reached the n-hexane extract (2.4 
g) and ethyl acetate extract (3.2 g). Ethyl acetate 
extract was fractionated using Si-gel vacuum 
liquid chromatography column (VLC) by using 
combination of eluent. Fractions collected in vial 
bottles. Each fraction of their chemical 
components were monitored by TLC using silica 
gel GF254 stationary phase and mobile phase ethyl 
acetate: methanol (25:1). The fraction which has 
spot with the same Rf value with the spot on TLC 
for every VLC was then combined to give 5 major 
fractions. Based on the TLC spots, the fractions 
which same with Lunacridine standard Rf value 
was fractions 2 (0.22 g). The fraction 2 was then 
further subjected with preparative TLC using Si-
gel as the adsorbent and was eluted with solvents 
of ethyl acetate: methanol (25:1) until obtained 
crystalline of Lunacridine. Identification had been 
done by TLC using Dragendorf reagent, UV-Vis 
and IR spectroscopies and compared by 
Lunacridine standard 
 
MTT Cytotoxic Test Method 
P388 murine cells was cultured in RPMI 
1640 medium complemented with 5% FBS (Fetal 
Bovine Serum) and Kanamycin (100 μg/ml). Cells 
(3 x 103 cells/well) were cultured in a microplate 
containing 100 μL per well growth medium and 
incubated at a temperature of 37
0
C in 5% CO2 
humidity atmosphere. Samples with various 
concentrations added to the culture on the day after 
transpalantation. On 72 hours, 20 μL of MTT 
solution (5 mg/ml) per well added into each culture 
medium. After 4 hours of incubation,  100 μL of 
SDS 10% solution - 0.01 N HCl added into each 
well and formazan crystals in each well was 
dissolved with stirring using micropipet. 
Measurement of optical density (OD) was done 
using a microplate reader at a wavelength of 550 
nm. Media containing only P388 murine cells used 
as positive control. As a comparison, we used 
Artonin E. Absorption measurement result 
implementated of cell death were plotted on the 
graph of the percentage of cell death versus the 
concentration of the test sample, then made a 
calculation of IC50. 
 
 x 100% 
 
 
 
 
 
RESULTS  
 
Molecular Docking  
1. Geometry Optimation.  
Molecular structure of lunacridine was 
optimized using the PM3 Semiempiric 
method. Optimization of this structure aims to 
obtain a stable molecular structure 
characterized by ΔHf value (entalphy of 
standart formation) which is minimum. Model 
of stable molecule can be used for the docking 
process. 
2. Docking Method Validation.  
Aims to validate the docking method. 
Validation of the docking performed in order 
to choose appropriate parameters to be used in 
the docking of new compounds. The value of 
RMSD (Root Mean Square Deviation) is used 
Zubair, et al., 2010 
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as a validation parameter. Docking method is 
said to be valid if the RMSD value of ≤ 2 Å. 
From the validation results obtained RMSD 
value of 1.15 Å indicating that the docking 
method performed already valid (Figure 2). 
 
 
 
 
Figure 2.  Superimposition in DNA-intercalation site of original ligand bis thiazole conformation from 
docking (red) and actual original ligand conformation (cyan) with RMSD value of 1,15 Å 
 
 
3. Docking Lunacridine Compound. 
Docking study was performed on 
Lunacridine with DNA model using 
AutoDock 4.0 software. DNA model was 
obtained from protein data bank website 
(www.rscb.org/pdb) with the archive code 
108D with original ligand bis thiazole. This 
model is a representation of DNA 
topoisomerase II enzyme and has been used by 
Filosa (2009) as a receptor in the development 
of  model bis-naftalamida compound as a new 
drug class of DNA topoisomerase II inhibitor 
with intercalating mechanism. 
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Figure 3.  3D models of the intercalation mode of Lunacridine compound (arrow) on DNA represented by 
molecular surface 
 
 
The docking aims to explore the affinity and 
molecular interaction of lunacridine to DNA. 
Binding free energy (kcal/mol) and inhibition 
constant (Ki) functions were used as parameter of 
ligand-receptor interaction strength. The docking 
result on DNA showed that score of lunacridine 
compound had higher score value compared to 
original ligand bis thiazole (Table 1). It explains 
that lunacridine compound affinity on DNA is 
relatively weak and the interaction of lunacridine 
with DNA is not stable if compared with original 
ligand. 
 
 
Table 1. Docking score (kcal/mol) and inhibition constant (μM) prediction of lunacridine 
Compound 
Predicted Free Binding Energy 
(kcal/mol) 
Predicted Inhibition Constant 
(μM) 
Lunacridine -6,22 27,51 
Original ligand -16,37 0,995 x 10-6 
 
Isolation and Identification of Lunacridine 
Isolation using preparative TLC obtained 
colorless crystalline (± 9 mg).  Identification of 
lunacridine isolated using TLC with Dragendorf 
reagent, UV-Vis and IR spectroscopy. The TLC 
results showed the same Rf values with lunacridine 
standard (Figure 5). 
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Figure 4.  Prediction of interaction between lunacridine compound and DNA 
 
 
 
 
 
Figure 5.  Identification of lunacridine isolated from ethyl acetate fraction of Sanrego (Lunasia amara 
Blanco) using eluent chloroform: methanol (18:1) after sprayed by dragendorf. 1: spot of 
lunacridine standar as comparison, and 2: spot of lunacridine isolated 
 
 
 
The colorless crystal obtained for 
lunacridine isolated compound has a UV spectrum 
as shown in Figure 6 with maximum absorbances 
at 204, 216, 240, 285, 298, 312, and 324 nm. This 
UV spectrum indicated there are subtituted group 
on quinoline ring (Noerdin, 1986). 
2 1 
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Figure 6.  UV-Vis spectrum of lunacridine isolated 
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Figure 7. IR spectrum of lunacridine isolated 
 
 
 
The IR spectrum of Lunacridine isolated 
compound (Figure 7) indicated absorption in KBr 
(cm
-1
 ): 3774,69, 3410,15, 2956,87-2854,65, 1737, 
86, 1641, 42, 1546,91, 1512,19, 1463,97, 1201,65, 
1170,79, 1116,78 and 750,31. The stretching at 
3774,69 cm
-1
  indicated the NH group. the strong 
stretching at 3410,15 cm
-1
 indicated the OH group, 
the present of aliphatic CH group shown by strong 
stretching at 2956,87-2854,65 cm
-1
, the present of 
secondary amide group shown by strong stretching 
at 1641,42 cm
-1
, the present of aromatic system is 
shown by the stretching at 1546,91-1512,19 cm
-1
, 
and the present of C-O/C-O-C group shown by the 
stretching at 1201,65; 1170,79 and 1116,78 cm
-1
 
(Silverstein, 2005). 
Based on the UV and IR spectroscopies data 
above, the values obtained are similar to 
Lunacridine reported by Ahmad et al. (2003), 
therefore it was suggested that the compound 
isolated is Lunacridine (Table 2) with the molecule 
structure as shown in Figure 1. 
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Table II.  The comparison of UV-Vis and IR spectrum datum of lunacridine (Ahmad, et al, 2003) and 
lunacridine compound isolated 
 
UV, λ max nm IR, cm-1 
Compound 
isolated 
Lunacridine Compound isolated Lunacridine 
204 - 3774,69 3500 – 3400 
216 - 3410,15 3500 – 3400 
240 240 2854,65; 2924,09;  2956,8 - 
285 256 1546,91;1512,19 1589, 1565 
298 286 1641,42 1647 
312 295 1201,65;1170,79; 1116,78 1240, 1209 
324 335 3774,69 3500 – 3400 
 
 
 
MTT Cytotoxic Test Method 
On testing the cytotoxic activity against 
P388 murine leukemia cells with a series of 
concentrations of 100, 30, 10, 3, and 1 μg/ml, 
lunacridine compound gave IC50 value of 39.52 
μg/ml or 129,41 μM (Table 3). IC50 value reached 
by regression analysis only using 3 concentrations 
(100, 30, and 10 μg/ml), because only these datum 
located on sigmoid area (Figure 8). According 
Muhtadi (2005), IC50
  
value above 4 μg/ml indicate 
that the compound had less cytoxicity on P388 
murine leukemia cells. 
 
 
Table III. Result of the cytotoxicy assay of lunacridine on P388 murine leukemia cells 
 
Sample 
Concentration   
(μg/ml) 
Cell death  
(%) 
IC50 
µg/ml μM 
Lunacridine 
100 83,000 
39,52 129,41 
30 40,428 
10 7,656 
3 13,629 
1 9,341 
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Figure 8. Cells death percentage of P388 murine leukemia cells exposed lunacridine for 72 hours 
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DISCUSSION  
 
The inhibitory potency of the compound on 
the receptor responsible for development of cancer 
drugs, could be studied by finding the interaction 
strength between the compound and the receptor 
through docking process. It is predicted that the 
potency will be higher when the interaction 
strength is stronger (Halperin, 2002). The 
cytotoxic effect caused by a drug compound is 
correlated by the docking result. This research 
showed that Lunacridine from  Lunasia amara  
Blanco has less cytotoxic activity on P388 murine 
leukemia cells with IC50 = 39,52 μg/mL or 129,41 
μM.  The less cytotoxic activity of lunacridine 
compound on P388 murine leukemia cells was 
strong reasonably. Based on the docking result, 
lunacridine compound has low affinity to interact 
with DNA with predicted binding free energy of -
6.22 kcal/mol and predicted inhibition constant of 
27,51 μM if compared with the predicted binding 
free energy and inhibiton constant of the original 
ligand bis thiazole of -16.37 kcal/mol and 0,995 x 
10
-6 
μM respectively. This result also show that 
lunacridine has binding energy higher than original 
ligand bis thiazol. It means that the interaction of 
lunacridine with DNA is not stable afford the less 
cytotoxic activity of lunacridine on cancer cells.   
The analysis of docking results accord with 
the ability of lunacridine to intercalate between 
base pairs of DNA, which had been reported by 
Prescott (2007). From docking simulation result 
gave ten model intercalations of lunacridine to 
DNA and lunacridine more prefer to intercalate 
between CG and TA base pairs than GC and AT 
base pairs, whereas the side chain of lunacridine  
located on the minor groove of  DNA. Quinoline 
ring of lunacridine could to perfectly intercalate 
between DNA base pairs and make л-л interaction 
with purine and pyrimidine bases of DNA because 
of the planar structure of quinoline ring (Figure 3).  
The active sites of lunacridine interacted to DNA 
are located on N heterosiclic of the quinoline ring, 
subtituent of methoxy group (-OCH3) on C8 of 
quinoline ring and subtituent of carboxyl group (-
C=O) on C2 of quinoline ring. The possibility 
interaction occurred with adenine, cytosine and 
thymine by dipole-dipole interaction. In details, the 
possibility interaction occured between N1 of 
quinoline ring and N1 of adenine, DA5 (3,51 Å), 
carboxyl group (-C=O) on C2 of quinoline ring 
and N3 of adenine, DA5 (3,18 Å),  methoxy group 
(OCH3) on C8 of quinoline ring and carboxyl 
group (C=O7) of thymine, DT4  (3,21 Å), N1 of 
quinoline ring with N3 of cytosine, DC3 (3,41 Å). 
The other subtituent such as methoxy group 
(OCH3) on C4 of quinoline ring, side chain of 
lunacridine and OH group on lunacridine side 
chain didn’t show dipole-dipole interaction with 
DNA (Figure 4). Therefore, this study suggest to 
modify these groups to increase the amount of 
molecular interaction of lunacridine to DNA and to 
increase the cytotoxic potency of lunacridine. 
Although there is a relationship between the 
binding free energy of lunacridine reached by 
docking simulation and its cytotoxic activity, as 
discussed above, cytotoxicity is not only 
dependent  on the ability to interact with DNA. 
According to Martinez (2005), there are also many 
DNA intercalators that are incapable of working as 
cytotoxic agents.  To be effective, a drug must first 
overcome many barriers, including metabolic 
pathways, and cytoplasmic and nuclear membranes 
(Martinez, 2005). Once the drug is situated in the 
nucleus, it must be capable of interacting with 
DNA by intercalating that is, forming a stable 
complex with a relatively long halflife. Achieving 
entry into the nucleus and forming a DNA 
complex are only the first stages of a series of 
events that underlie the cytotoxic activity of DNA 
intercalators, thus cytotoxicity is more than just an 
interaction with DNA. Cytotoxicity is a 
consequence of the poisoning of topoisomerase, 
enzymes that are directly involved in DNA 
recognition, in the fundamental steps of cellular 
growth when DNA replication is active, in the S 
phase of the cell cycle, in which the topology of 
DNA plays a significant role. Topoisomerase 
enzim also work and can be poisoned, in the M 
phase of the cell cycle and arranging the 
chromatin.  
By this study, we know that lunacridine 
could be as a lead compound for anticancer drug 
based on the IC50 value on P388 murine leukemia 
cells and the ability to intercalate on DNA. 
Therefore, it is needed further study to increase the 
cytotoxic activity of lunacridine by considering 
some factors mentioned above such as affinity and 
molecular interaction with DNA, the absorpsion 
ability on cell membrane, the polarity properties, 
and the ability to form stable complex with DNA 
with a relatively long halflife. 
 
CONCLUSION 
  
From docking simulation of lunacridine to 
DNA, gave the result of predicted binding energy 
of lunacridine on DNA is -6,22 kcal/mol, whereas 
original ligand bis thiazole is -16,37 kcal/mol. 
Binding energy of lunacridine higher than original 
ligand show that the interaction of lunacridine with 
DNA by intercalating mechanism is not stable 
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afford the less cytotoxic activity of lunacridine on 
cancer cells. The ability of lunacridine to 
intercalate on DNA based on the planar structure 
of the quinoline ring. 
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